Annual report pursuant to Section 13 and 15(d)

Intangible Assets (Details Narrative)

v3.21.1
Intangible Assets (Details Narrative) - USD ($)
12 Months Ended
Mar. 19, 2018
Dec. 31, 2020
Dec. 31, 2019
Amortization expense   $ 795,328 $ 795,328
Future amortization expense   $ 790,000 $ 788,000
Common stock shares issued   14,187,984 5,486,595
Common stock shares outstanding   14,187,984 5,486,595
CoNCERT Pharmaceuticals, Inc [Member] | License Rights [Member]      
Purchase price $ 8,000,000    
Transaction cost 1,782    
Recognition of deferred tax liability 3,037,147    
Intangible asset, tax basis $ 1,782    
Number of shares distributed in exchange for license agreement 298,615    
Shares acquired price per share $ 26.79    
Common stock shares issued 5,039,033    
Common stock shares outstanding 5,039,033